Toshiba adds to management
Toshiba America Medical Systems has named Geraldine Goodstone to the post of director of healthcare business development. Goodstone fills a position left empty by Robert Kreps, now vice president of sales. The move is the latest in a string of management
Toshiba America Medical Systems has named Geraldine Goodstone to the post of director of healthcare business development. Goodstone fills a position left empty by Robert Kreps, now vice president of sales. The move is the latest in a string of management shifts at the Tustin, CA-based company that began in 1998.
Goodstone joined Toshiba in 1997 as corporate manager for the companys healthcare business development department. She will help Toshiba seek and secure purchase agreements with integrated delivery networks and group purchasing organizations. The company already has agreements with Tenet Healthcare, Appalachian Regional Healthcare, Shared Services Healthcare, and West Florida Medical Center.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
